The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Guidance on the use of epcoritamab for the treatment of follicular lymphoma
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, provides guidance on the use of epcoritamab for treating follicular lymphoma. He discusses administration, the occurrence of cytokine release syndrome, and measures to prevent infections. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that one of the most important points for epcoritamab is that it is a bispecific antibody that is given through subcutaneously and this is very easy to use either for the patient and also for the healthcare resources because it’s very easy to administer. The second point that the CRS is highly predictable because it occurs when it occurs only low grade at the first full dose that with the introduction of the third step up dose it means on day 21 and also the CRS is very very short I mean only some fever that you can manage easily with paracetamol and so in this way epcoritamab can be given in an outpatient treatment...
I think that one of the most important points for epcoritamab is that it is a bispecific antibody that is given through subcutaneously and this is very easy to use either for the patient and also for the healthcare resources because it’s very easy to administer. The second point that the CRS is highly predictable because it occurs when it occurs only low grade at the first full dose that with the introduction of the third step up dose it means on day 21 and also the CRS is very very short I mean only some fever that you can manage easily with paracetamol and so in this way epcoritamab can be given in an outpatient treatment. And it’s important of course for the patient for the physician and we have to check carefully because if there is some sign of infection during the treatment of epcoritamab because we need to intervene early just to prevent infection.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
